{"schema_version":"secwatch.filing_event.v1","accession":"0001607062-21-000626","form_type":"8-K","ticker":"RGBP","cik":"0001589150","company_name":"Regen BioPharma Inc","filed_at":"2021-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.174560+00:00","generated_at":"2026-06-27T23:42:32.915819+00:00","sec_items":["8.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Regen Biopharma pays down $1.02M of convertible notes, principal now $1.34M","bullets":["Principal indebtedness on convertible notes reduced from $2,364,075 (Jun 30) to $1,340,621 (Dec 13, 2021).","Company satisfied $1,023,454 of principal debt between July 1 and Dec 13, 2021.","This represents a 43% reduction in principal debt over approximately 5.5 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001607062-21-000626","json":"https://secwatch.observer/filing/0001607062-21-000626.json","markdown":"https://secwatch.observer/filing/0001607062-21-000626.md","text":"https://secwatch.observer/filing/0001607062-21-000626.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1589150/000160706221000626/0001607062-21-000626-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1589150/000160706221000626/rgbp122021form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T23:42:32.915819+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}